Analyst Tyler Van Buren from TD Cowen maintained a Buy rating on Soleno Therapeutics and keeping the price target at $120.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tyler Van Buren has given his Buy rating due to a combination of factors centered on Soleno Therapeutics’ updated financial outlook and underlying growth narrative. In revising his model ahead of the company’s Q4 2025 earnings, he incorporated the pre-announced full-year 2025 revenue, which reinforced confidence in the near‑term revenue trajectory. This visibility into upcoming results, combined with only modest changes to projected 2026 sales, suggests that the company’s core commercial assumptions remain intact and supportive of upside potential.
At the same time, Van Buren raised his 2026 operating expense forecasts more meaningfully, but this appears to be viewed as strategic investment rather than a deterioration of the story, implying management is spending to support future growth. The balance of slightly stronger forward revenue expectations with higher but manageable OpEx underpins his constructive stance on earnings power beyond 2025. Taken together, these model adjustments indicate that the risk/reward profile remains favorable, which supports his Buy recommendation on Soleno Therapeutics shares.
Van Buren covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics, Gilead Sciences, and Moderna. According to TipRanks, Van Buren has an average return of 20.1% and a 54.15% success rate on recommended stocks.
In another report released on January 26, Cantor Fitzgerald also maintained a Buy rating on the stock with a $123.00 price target.